A First‐In‐Human, Randomized, Placebo‐Controlled Single and Multiple Ascending Dose Study of Izicopan (INF904), A Second‐Generation Oral Small Molecule C5a Receptor Inhibitor, in Healthy Participants

Joseph F. Grippo, Anja Pfaff, Zhongli Xu, Isabell Otto, Claus Thielert, Mihaly Imre, Rui Liu, Wantanee Phuapradit, Yazhong Pei, Cuie Chen, Maria Habel, Renfeng Guo, Camilla Chong
Clinical Pharmacology in Drug Development · Wiley · 2026-11-02 · DOI: 10.1002/cpdd.70123

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles